April 12, 2007
MOLECULAR MEDICINE’S “BEST OF SHOW”
At the CHI Molecular Medicine Tri-Conference, which drew more than 2000 attendees to San Francisco in February, delegates voted for the “Best of Show” organizations releasing new products from more than 25 exhibitors.
And the winners in five categories were:
BIOBASE: BIOBASE ExPlain System
• Preclinical Development
Biotrin International: Early Biomarker
• Medicinal Chemistry
Chemical Computing Group: MOE 2006.08
• Molecular Diagnostics
Luminex: FlexmiR mircoRNA
• Pathway Analysis
GeneGo: MetaDrug 2.0
Novartis has decided to dissolve its Genome & Proteome Sciences program, currently based in the Novartis Institutes for Biomedical Research (NIBR) facility in Cambridge, Mass. The company plans to restructure and “refocus” the resources and programs assocaited with the group, and expects most staff and programs will be absorbed by other units. Program head Mark Boguski is leaving the NIBR for other opportunities.
CuraGen Corporation and Roche announced that 454 Life Sciences, a subsidiary of CuraGen, and Roche have signed a merger agreement under which Roche will acquire 454 Life Sciences for about $155 million. 454 develops high-throughput DNA sequencing technology. Roche plans to maintain the 454 Life Sciences facility in Connecticut, with its 167 employees as an integrated part of Roche Diagnostics.